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BACKGROUND: Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumour and antiangiogenic activity. We investigated
the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients with advanced, refractory solid tumours.
METHODS: Sunitinib was initially administered once daily at 37.5mg per day on days 1–14 of a 21-day cycle, in which irinotecan
250mgm
 2 was given on day 1. In a second cohort, the sunitinib dose was reduced to 25mg per day. Blood samples were collected
for pharmacokinetic studies.
RESULTS: In the sunitinib 37.5mg per day cohort, 3 out of 10 evaluable patients had objective responses, but dose-limiting toxicities
(DLTs) of neutropenia, pneumococcal sepsis, and fatigue were observed. There were no DLTs in the sunitinib 25mg per day cohort.
Paired observations of pharmacokinetic parameter values of sunitinib and irinotecan alone vs the combination did not reveal
significant drug–drug interactions. The maximum tolerated dose was defined as sunitinib 25mg per day (days 1–14) with irinotecan
250mgm
 2 (day 1), but no activity was observed at this dose.
CONCLUSION: Although a higher sunitinib dose of 37.5mg per day (days 1–14) with irinotecan showed preliminary evidence
of antitumour activity, this dose was poorly tolerated. Therefore, this particular combination will not be pursued for further studies.
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The addition of targeted agents to standard chemotherapy is
becoming widely investigated in a number of advanced solid
tumour types, and has met with success in some malignancies,
including colorectal cancer (CRC). The combination of the
vascular endothelial growth factor (VEGF)-targeted monoclonal
antibody bevacizumab with either irinotecan/5-fluorouracil
(5-FU)/leucovorin (LV) (FOLFIRI) or oxaliplatin/5-FU/LV (FOL-
FOX) has shown increased median progression-free survival and/
or overall survival in patients with advanced CRC as compared
with chemotherapy alone (Hurwitz et al, 2004, 2005; Giantonio
et al, 2007). The optimal role of targeted agents, sequencing of
therapies, and primary tumour resistance as well as resistance
development are under investigation in advanced CRC (Gravalos
et al, 2007), as more effective treatment regimens are still needed.
Sunitinib is an oral tyrosine kinase inhibitor that is known
to block the signalling activity of VEGF receptors (VEGFR-1, -2,
and -3), platelet-derived growth factor receptors (-a and -b),
stem-cell factor receptor (KIT), FMS-like tyrosine kinase 3,
colony-stimulating factor-1 receptor, and rearranged during
transfection (RET) ligand; glial cell line-derived neurotrophic
factor receptor (Abrams et al, 2003; Mendel et al, 2003; Murray
et al, 2003; O’Farrell et al, 2003; Kim et al, 2006). It is approved
multinationally for the treatment of advanced renal cell cancer and
imatinib-resistant/-intolerant gastrointestinal stromal tumours
(Goodman et al, 2007). The tolerability profile of sunitinib is well
established, and adverse events (mainly diarrhoea, mucositis, skin
abnormalities, and altered taste) are generally manageable and
reversible (Demetri et al, 2006; Motzer et al, 2007). In addition,
hypertension and fatigue have been reported with sunitinib and
are, in general, common side effects of VEGF pathway-targeted
therapies (Demetri et al, 2006; Hutson et al, 2008; Launay-Vacher
and Deray, 2009). Promising single-agent antitumour activity
across patients with a range of solid tumour types has been
observed in phase I and II trials of sunitinib, including
neuroendocrine tumours, breast cancer, hepatocellular cancer,
and non-small-cell lung cancer (NSCLC; Burstein et al, 2008; Kulke
et al, 2008; Socinski et al, 2008; Faivre et al, 2009). Single-agent
sunitinib has also shown modest antitumour activity in patients
with metastatic CRC refractory to standard chemotherapy in a
phase II trial (Saltz et al, 2007), suggesting that a study of sunitinib
in combination with standard chemotherapy for metastatic CRC is
warranted.
The established topoisomerase I inhibitor irinotecan (CPT-11),
a derivative of the natural alkaloid camptothecin, prevents repair
of single-strand breaks in DNA, resulting in double-strand
DNA damage and cell death. Irinotecan is approved for treatment
of advanced/metastatic CRC. The drug has also demonstrated
antitumor activity in glioblastoma and both small-cell and NSCLC
(Fukuoka et al, 1992; Masuda et al, 1992; Friedman et al, 1999).
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III trial of single-agent irinotecan administered every 3 weeks were
neutropenia, diarrhoea, and vomiting (Fuchs et al, 2003).
The activity of sunitinib and irinotecan, together with their
manageable and generally nonoverlapping toxicity profiles,
suggests that combining the two agents may be beneficial in
a broad range of solid tumours, particularly CRC. Here, we
report results from a phase I, dose-finding study of sunitinib
and irinotecan in patients with advanced solid tumours and
included plasma pharmacokinetics assessed for the drugs alone
and combined.
PATIENTS AND METHODS
Study design and treatment regimen
Sunitinib and irinotecan were administered in 3-week cycles, up to
a maximum of 12 cycles. Seven days before the start of cycle 1,
a single day’s dose of sunitinib was administered to allow for
the collection of samples for pharmacokinetic analysis. Patients
subsequently received sunitinib as once-daily oral doses on
days 1–14 followed by a 1-week break, and irinotecan as a 1-h
intravenous infusion on day 1.
For combination of sunitinib and irinotecan, starting doses
were selected being 75% of single-agent doses, that is, sunitinib
37.5mg (50mg daily oral dose as single agent) and irinotecan
250mgm
 2 (350mgm
 2 3-weekly i.v. dose as single agent).
The study design allowed for sunitinib a dose escalation to
50mg and de-escalation to 25mg, whereas the initial dose of
irinotecan could be escalated to 300 or 350mgm
 2. Concomitant
medication precluded, among others, potent CYP3A4 inhi-
bitors and inducers. In addition, prophylactic use of hemato-
poietic growth factors to support neutrophil or platelet counts
was not recommended in cycle 1, but could be used in subsequent
cycles.
Dose-limiting toxicity (DLT) was defined as any of the following
events occurring during the first 2 cycles of treatment that were
attributable to the study drug combination: grade 4 neutropenia
lasting X7 days; febrile neutropenia (grade 3 or 4 neutropenia and
fever X38.51C); neutropenic infection (grade 3 or 4 neutropenia
with Xgrade 3 infection); either grade X3 thrombocytopenia with
bleeding, or grade 4 thrombocytopenia lasting X7 days; grade 3 or
4 nonhaematological toxicities including fatigue lasting X7 days
(except for skin or hair discolouration, alopecia, hyperamylasae-
mia, or hyperlipasaemia without other clinical evidence of
pancreatitis, and asymptomatic hyperuricaemia; nausea, vomiting,
or diarrhoea had to persist at grade 3 or 4 despite maximal medical
therapy to qualify for DLT). MTD was the primary endpoint of the
study, defined as the dose level at which none or one out of six
patients experienced a DLT, with the next higher dose level having
at least two out of three or two out of six patients encountering
DLT during the first 2 cycles of combination therapy.
The study was conducted with institutional review board/
independent ethics committee approval and in accordance with the
International Conference on Harmonisation Good Clinical Practice
guidelines, as well as applicable local laws and regulatory
requirements. All patients provided written informed consent.
Patient eligibility
Patients eligible for the study had histologically or cytologically
proven advanced malignancy refractory to standard therapy, or for
which no curative therapy was available, and were suitable for
treatment with irinotecan; Eastern Cooperative Oncology Group
performance status of 0 or 1, and a life expectancy X12 weeks.
Patients were excluded if they had received chemotherapy,
radiation therapy, surgery, or investigational agent within 4 weeks
before study entry, or previous irradiation to 425% of the
bone marrow, grade X2 neuropathy (any cause), uncontrolled
brain metastases, myocardial infarction, severe/unstable angina,
coronary/peripheral artery bypass graft, congestive heart failure,
cerebrovascular accident including transient ischaemic attack,
or pulmonary embolus within the 12 months before starting
study treatment. Patients with uncontrollable hypertension
(4150/100mmHg), grade 3 haemorrhage o4 weeks before
starting study treatment, cardiac dysrhythmias (grade X2), atrial
fibrillation, QTc interval 4450ms (males) or 4470ms (females),
or a history of grade 3 or 4 toxicity or severe hypersensitivity
reaction associated with previous irinotecan treatment were also
excluded.
Patient assessments
The number of patients to be enroled was to be determined by
the observed safety profile, which also determined the number
of patients per dose level and the number of dose escalations.
All patients who received at least one dose of study medication
were included in the study analyses.
Patients underwent regular physical examinations (usually on
day 1 of each treatment cycle), laboratory tests (blood, usually
on days 1 and 15 of each cycle, and urinalysis) and 12-lead
electrocardiogram (at screening, at steady state level of sunitinib
on cycle 2 day 1, and as clinically indicated in subsequent cycles).
Adverse events were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events (NCI
CTCAE), version 3.0 (http://ctep.cancer.gov/protocoldevelopment/
electronic-applications/docs/ctcaev3.pdf). Tumour measurements
were assessed at screening, at every third cycle of chemotherapy,
and when disease progression was suspected. Response Evaluation
Criteria for Solid Tumors version 1.0 (Therasse et al 2000) was
used, requiring repeat imaging studies X4 weeks after the initial
documentation of response.
Pharmacokinetics
Pharmacokinetic analysis was carried out in a central laboratory,
and pharmacokinetic parameter values were estimated using
noncompartmental methods. Human potassium EDTA plasma
pharmacokinetic samples were analysed for sunitinib and
SU012662 and total drug (sunitinib plus SU012662) concentrations
at BASi (West Lafayette, IN, USA) with the use of a validated,
sensitive, and specific liquid chromatographic-tandem mass
spectrometric method. The performance of the method during
validation has been documented in the method validation report
(BASi report 1000-05793-1). Plasma specimens were stored at
 201C until assay, and all samples were analysed within the 377
days of established stability. Calibration standard responses met
acceptance criteria over the range of 0.100 to 60.0ngml
 1 for
sunitinib and 0.100 to 20.0ngml
 1 for SU012662 using a quadratic
regression with 1/concentration
2 weighting. The lower limit
of quantitation (LLOQ) for both sunitinib and SU012662 was
0.100ngml
 1. The between-day assay accuracy, expressed as the
ratio (%) of the estimated to the theoretical quality control (QC)
concentrations, ranged from  1.1 to 1.3% for the low, medium,
and high sunitinib QCs and from  1.0 to 3.6% for the low,
medium, and high SU012662 QCs. Assay precision, expressed as
the between-day coefficients of variation (%) of the estimated
concentrations of QC samples, was p6.5% for the low, medium,
and high sunitinib QCs and p6.9% for the low, medium, and high
SU012662 QCs.
Human sodium heparin plasma pharmacokinetic samples were
analysed for irinotecan and SN-38 concentrations at Eurofins
AvTech Laboratories (Portage, MI, USA) using a validated,
sensitive, and specific high performance liquid chromatographic
method with fluorescence detection. The performance of the
method during validation has been documented in the method
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The plasma specimens were stored at  201C until assay, and all
samples were assayed within the 1860 days (for irinotecan) and
1020 days (for SN-38) of established stability. Calibration standard
responses met acceptance criteria over the range of 1.28 to
3840ngml
 1 for irinotecan and 0.480 to 640ngml
 1 for SN-38,
using a linear regression with 1/concentration weighting. The
LLOQ was 1.28ngml
 1 for irinotecan and 0.480ngml
 1 for SN-38.
The between-day assay accuracy ranged from  0.7 to 3.8% for the
low, medium, and high irinotecan QCs and from  8.0 to 3.2% for
the low, medium, and high SN-38 QCs. Assay precision was p6.3%
for the low, medium, and high irinotecan QCs and p7.1% for the
low, medium, and high SN-38 QCs.
Sunitinib was assessed on day  7 (i.e., 1 week before cycle 1);
samples were taken pre-dose and at 1, 2, 4, 6, 8, 10, and 24h post-
dose. Irinotecan was evaluated on cycle 1 day 1; samples were
taken before infusion and at 1, 1.5, 2, 4, 6, 8, 10, and 24h after the
start of treatment. In cycle 1, sunitinib administration started on
day 2. Both agents were evaluated in combination on cycle 2 day 1;
samples were drawn before drug administration and at 1, 1.5, 2, 4,
6, 8, 10, and 24 hours post-dose.
Pharmacokinetic parameter values were calculated for each
subject by noncompartmental analysis of concentration–time data
using WinNonlin version 4.1 (http://pharmacy.ucsf.edu/irc/pdfs/
wul_users_guide.pdf). Actual sample collection time was used for
sunitinib, SU012662, total drug, irinotecan, and SN-38. If pre-dose
concentration for an individual was 45% of Cmax, a carryover
correction was made as recommended by FDA guidance (FDA,
2003). Summary descriptives of pharmacokinetic values were
presented only for paired observations with respect to each
analyte. In the case where the dose for one of the paired
observations was different from the other observation, dose
correction to the intended dose was performed (correction factor:
intended dose/actual dose). Dose correction to the MTD was
performed. Individual patient trough plasma concentrations were
summarised per cycle and study day. All concentrations that
were below the limits of quantitation (BLQ) were set to zero before
computation of descriptive statistics (BLQ values were excluded
from the calculations of geometric means and the associated 95%
confidence intervals).
Standard plasma pharmacokinetic parameters were used
including the maximum plasma concentration (Cmax), time
to Cmax (Tmax), area under the plasma concentration–time curve
to the time of the last measurable concentration (AUC0–last)o r
infinity (AUC0–N), clearance, and terminal elimination half-life
(t1/2). The geometric mean ratio was used to give a robust
measurement of differences in exposure in rate (Cmax) and extent
(AUC), with values below 0.8 or above 1.25 suggesting differences
between reference and test treatment.
RESULTS
Patient baseline characteristics
A total of 21 patients were enroled in the study, which finally
comprised two cohorts (Table 1). Patients in each cohort had been
pretreated for a variety of tumour types: all had received chemo-
therapy, and several had received other treatments including radiation
therapy (n¼11), hormones (n¼1), or other agents (n¼4).
Treatment, dose reductions, and discontinuations
Because of DLT encountered in two out of six patients at the
starting dose level, sunitinib was de-escalated to 25mg per day. In
a later stage the protocol was amended to expand cohorts
with patients who had received no more than two previous
chemotherapy regimens and had aspartate aminotransferase and
alanine aminotransferase serum levels o2.5 upper limit of
normal (ULN; was o5 ULN).
All patients received at least one full cycle of treatment, either at
the sunitinib 37.5mg per day (cohort 1) or at the sunitinib 25mg
per day (cohort 2) dose level. Those in cohort 1 received a median
of six cycles of both sunitinib and irinotecan, whereas patients in
cohort 2 received a median of 3 cycles of each agent. The majority
of discontinuations from the study were due to lack of efficacy
(n¼8 in cohort 1; n¼6 in cohort 2). Discontinuation due to
adverse events during cycles 1 and 2 occurred in one patient, who
experienced grade 3 febrile neutropenia and grade 5 pneumococcal
sepsis.
During cycles 1 and 2, dose delay of sunitinib for X1 week was
required in three patients in cohort 1 and was not required in
cohort 2; delays were required for irinotecan in four and one
patients in cohorts 1 and 2, respectively.
Dose reductions of sunitinib occurred in three patients in cohort
1 during cycles 1 and 2, and were not required in cohort 2;
no patients required more than one sunitinib dose reduction.
For irinotecan, six patients in cohort 1 and one patient in cohort 2
required dose reduction during the first two cycles of treatment.
DLTs, safety, and tolerability
In the sunitinib 37.5mg per day group, including the expansion of
this cohort, a total of four patients experienced a grade 3 or 4
adverse event during the first 2 cycles of treatment that was
categorised as DLT: two patients had grade 4 neutropenia, one
patient had grade 5 pneumococcal sepsis, and one patient had
grade 3 fatigue. At the de-escalated dose of sunitinib 25mg per day
in cohort 2, no DLTs were observed, and the MTD was therefore
defined as this dose level.
One patient in the sunitinib 37.5mg per day group discontinued
from the study because of a treatment-related adverse event
(reactivation of hepatitis B). There were four deaths during the
study, of which three were due to adverse events that were
considered to be related to treatment with irinotecan and
sunitinib: neurological disorder (n¼1; cohort 2), septic shock
Table 1 Patient baseline characteristics
Cohort 1 sunitinib
37.5mg per
dayþirinotecan
250mgm
 2
(n¼11)
Cohort 2 sunitinib
25mg per
dayþirinotecan
250mgm
 2
(n¼10)
Median (range) age, years 50 (42–62) 51 (32–67)
Male/female, n (%) 8 (73)/3 (27) 4 (40)/6 (60)
ECOG performance status, n (%)
0 6 (55) 3 (30)
1 5 (45) 6 (60)
2 0 1 (10)
Tumour types, n
Colorectal carcinoma 1 3
Non-small-cell lung carcinoma 2 1
Cervical carcinoma 1 2
Head-and-neck tumour 2 0
Breast carcinoma 0 1
Gall bladder carcinoma 1 0
Gastric carcinoma 1 0
Mesothelioma 1 1
Osteosarcoma 1 0
Prostate carcinoma 0 1
Soft tissue sarcoma 1 0
Mediastinal carcinoid 0 1
Abbreviation: ECOG, eastern cooperative oncology group.
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fever (n¼1; cohort 1).
The most frequent adverse events of any cause during cycles 1
and 2 (all seen in X60% of patients overall) were vomiting,
diarrhoea, and neutropenia. Events occurring in 425% of patients
overall during cycles 1 and 2 are shown in Table 2.
Adverse events in patients receiving sunitinib 25mg per day
with irinotecan were predominantly grade 1 or 2 and nonhaema-
tological in nature. In these patients, the most common grade X3
all-causality adverse events in cycles 1 and 2 were neutropenia
(n¼2) and vomiting (n¼2; Table 3). In patients receiving sunitinib
37.5mg per day with irinotecan, the most common grade X3
adverse events during the first two cycles were haematological:
neutropenia (n¼8) and leukopenia (n¼6; Table 3).
Efficacy
T h em a j o r i t yo fp a t i e n t s( 1 0o u to f1 1p a t i e n t si nt h es u n i t i n i b3 7 . 5m g
per day group and all 10 patients in the 25mg per day group) had
measurable disease at baseline, and were available for assessment of
tumour response (Table 4). Out of 10 evaluable patients, 3 (30%) in
cohort 1 had a confirmed partial response: one patient with
submandibular cancer, one patient with oropharyngeal cancer who
experienced complete regression of the target lesion in the presence
of persisting non-target lesions, and one patient with relapsed
NSCLC. Figure 1 shows durable tumour shrinkage in the patient with
NSCLC. A further two patients in cohort 1 experienced stable disease
for X12 weeks (one patient each with CRC and leiomyosarcoma). In
cohort 2, two patients (one patient each with prostate cancer and
cervical cancer) had a best resp o n s eo fs t a b l ed i s e a s ef o rX12 weeks.
Tumour response assessments (percentage change from baseline in
sum of target lesions) are shown for individual patients in Figure 2.
Table 2 Adverse events (AEs) occurring in 425% of patients during cycles 1 and 2 and during all cycles (all grades, all causalities)
Cohort 1 sunitinib 37.5mg
per dayþirinotecan 250mgm
 2 (n¼11)
Cohort 2 sunitinib 25mg
per dayþirinotecan 250mgm
 2 (n¼10)
AE, n (%) Cycles 1 and 2 All cycles Cycles 1 and 2 All cycles
Neutropenia 11 (100) 11 (100) 6 (60) 6 (60)
Nausea 8 (73) 8 (73) 4 (40) 9 (90)
Vomiting 6 (55) 8 (73) 8 (80) 9 (90)
Leukopenia 9 (82) 10 (91) 4 (40) 5 (50)
Diarrhoea 9 (82) 9 (82) 6 (60) 6 (60)
Anorexia 7 (64) 8 (73) 2 (20) 4 (40)
Asthenia 5 (45) 6 (55) 4 (40) 5 (50)
Abdominal pain 6 (55) 6 (55) 4 (40) 5 (50)
Alopecia 5 (45) 7 (64) 4 (40) 4 (40)
Fatigue 4 (36) 4 (36) 3 (30) 5 (50)
Headache 3 (27) 4 (36) 4 (40) 5 (50)
Dyspnoea 3 (27) 3 (27) 4 (40) 6 (60)
Anaemia 3 (27) 6 (55) 3 (30) 3 (30)
Mucosal inflammation 5 (45) 5 (45) 1 (10) 2 (20)
Thrombocytopenia 3 (27) 4 (36) 2 (20) 2 (20)
Table 3 Most frequent (occurred in X2 patients) adverse events (AEs), grade X3, all causalities
Cohort 1 sunitinib 37.5mg
per dayþirinotecan 250mgm
 2 (n¼11)
Cohort 2 sunitinib 25mg
per dayþirinotecan 250mgm
 2 (n¼10)
AE, n (%) Cycles 1 and 2 All cycles Cycles 1 and 2 All cycles
Haematological
Neutropenia 8 (73) 8 (73) 2 (20) 3 (30)
Leukopenia 6 (55) 6 (55) 1 (10) 1 (10)
Anaemia 1 (9) 2 (18) 1 (10) 1 (10)
Thrombocytopenia 0 1 (9) 1 (10) 1 (10)
Nonhaematological
Asthenia 2 (18) 3 (27) 1 (10) 3 (30)
Vomiting 1 (9) 2 (18) 2 (20) 3 (30)
Fatigue 1 (9) 1 (9) 1 (10) 2 (20)
Nausea 1 (9) 1 (9) 0 1 (10)
Abdominal pain 0 1 (9) 1 (10) 1 (10)
Gamma glutamyl transferase increase 1 (9) 2 (18) 0 0
Table 4 Patients’ best tumour response to treatment according to
RECIST 1.0
Patients,
n (%)
Cohort 1 sunitinib 37.5mg
per dayþirinotecan
250mgm
 2 (n¼10)
Cohort 2 sunitinib 25mg
per dayþirinotecan
250mgm
 2 (n¼10)
Partial response 3 (30) 0
Stable disease
X12 weeks
2 (20) 2 (20)
Progressive
disease
3 (30) 4 (40)
Not evaluable 2 (20) 4 (40)
Abbreviation: RECIST 1.0¼Response Evaluation Criteria in Solid Tumors version 1.0.
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A summary of paired observations with respect to each analyte is
shown in Table 5. Data for the 25mg per day and 37.5mg per day
dose levels of sunitinib were reported in combination after dose
correction to the MTD (25mg for sunitinib and 250mgm
 2 for
irinotecan). Where doses differed within paired observations, dose
corrections to the intended dose were also performed. Based on
this analysis, changes in pharmacokinetic values for sunitinib, total
drug (sunitinibþSU012662), irinotecan, and SN-38 were within
the range of variability of the data. SU012662 presented higher
geometric mean ratios, which was mostly due to an apparent lower
plasma exposure with the first dose (day  7; sunitinib alone).
For patients in both cohorts combined, the geometric mean
ratios (sunitinibþirinotecan relative to sunitinib alone and
sunitinibþirinotecan relative to irinotecan alone) of the pharma-
cokinetic parameter that related to maximum and total plasma
exposure (i.e., Cmax, AUC0–last and AUC0–N) were calculated. The
geometric mean ratios (sunitinibþirinotecan relative to sunitinib
alone) of Cmax and AUC0–last, for both cohorts combined were 0.82
and 0.88, respectively. Similarly, the geometric mean ratios for
total drug were 0.90 and 0.95 for Cmax and AUC0–last, respectively,
suggesting that the pharmacokinetics of sunitinib when coadmi-
nistered with irinotecan did not appear to change as compared
with when it was administered alone.
The higher geometric mean ratios and apparent lower plasma
exposure of SU012662 could potentially have been related to low-
capacity tight/target tissue binding sites, which would be only
present after the first dose at very low concentrations with limited
sampling. Therefore, the increase in the geometric mean ratios for
SU012662 was potentially caused by the limited sampling scheme
and not because of a decrease in the elimination of the metabolite
when sunitinib was coadministered with irinotecan as compared
with its administration alone.
The geometric mean ratios (sunitinibþirinotecan relative to
irinotecan alone) of Cmax, AUC0–last and AUC0–N for both cohorts
combined were 1.21, 1.12, and 1.13, respectively. Similarly, the
geometric mean ratios of Cmax and AUC0–last for SN-38 were 1.13
and 1.20, respectively. Therefore, based on these data, coadminis-
tration of sunitinib with irinotecan did not appear to affect the
pharmacokinetics of irinotecan or its active metabolite SN-38.
DISCUSSION
The current standard of care for treatment of patients with
advanced CRC is FOLFOX or FOLFIRI with bevacizumab. Based on
the rationale for combining a tyrosine kinase inhibitor of VEGFRs
with chemotherapy, the combination of sunitinib plus irinotecan
might offer efficacy in this patient category. In our dose-finding
Figure 1 Partial response in a patient with inoperable non-small-cell lung cancer receiving sunitinib 37.5mg per day and irinotecan. CT scans are shown
at baseline (A), after 7 weeks (B) and 6 months (C) on treatment.
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Figure 2 Percentage change from baseline in sum of target lesions (mm) in patients assessed for treatment response.
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treated with the higher dose of sunitinib 37.5mg per day in
combination with irinotecan. At this dose, one patient with NSCLC
and two with tumours in the head-and-neck region achieved a
partial response. A further two patients (one patient each with CRC
and leiomyosarcoma) maintained stable disease for X12 weeks. It
may be that durable stable disease, rather than objective response,
is the main efficacy benefit when sunitinib is added to
chemotherapy. The lower-dose regimen (sunitinib 25mg per day
with irinotecan), however, did not result in clinically meaningful
responses.
Our dose-finding study indicated that in combination with
irinotecan, the sunitinib dose of 37.5mg per day was not well
tolerated, with DLTs (including grade 4 neutropenia, grade 5
pneumococcal sepsis, and grade 3 fatigue) reported in four patients.
Therefore, the MTD was determined to be sunitinib 25mg per day, a
dose level which was not associated with any DLTs. Indeed, the
tolerability and safety results from this study in pretreated patients
show that sunitinib 25mg per day (days 1–14) with irinotecan
250mgm
 2 (day 1) in a 21-day cycle has a manageable safety profile.
Most adverse events were mild–moderate at this dose, and
haematological events, especially neutropenia and leukopenia,
occurred at a lower frequency as compared with the higher dose.
Toxicities due to irinotecan normally include neutropenia,
diarrhoea, and vomiting (Fuchs et al, 2003). In our study, these
were among the most common all-causality adverse events,
occurring in more than half of patients during cycles 1 or 2.
Irinotecan/SN-38 toxicity is known to be affected by genetic and
physiological variation in uridine-diphosphoglucuronosyl transfer-
ase 1A1 (UGT1A1) enzyme activity. Genotyping of UGT1A1 to
permit potential reduction of drug dosing in patients with the
UGT1A1*28 polymorphism is increasingly being carried out to
avoid severe toxicities (Deeken et al,2 0 0 8 ;F u n k eet al, 2008; Rouits
et al, 2008). Although 250mgm
 2 is a relatively low irinotecan dose,
two patients in this study who developed grade 4 neutropenia within
the first 2 weeks of cycle 1 were found to have decreased metabolism
of SN-38 to its metabolite SN-38-glucuronide because of a
UGT1A1*1/*28 and UGT1A1*28/*28 genotype, respectively.
The pharmacokinetic parameter values for sunitinib, SU012662,
total drug (sunitinib þ SU012662), irinotecan, and its active
metabolite were consistent with data previously reported for
sunitinib (Faivre et al, 2006; Britten et al, 2008), as well as for
irinotecan (Rea et al, 2005; Camptosar, 2008). For patients in both
cohorts combined, the geometric mean ratios (sunitinibþ
irinotecan relative to sunitinib alone, and sunitinibþirinotecan
relative to irinotecan alone) of the pharmacokinetic parameters
that related to maximum and total plasma exposure (i.e. Cmax,
AUC0–last, and AUC0–N, respectively) were calculated. It could be
concluded that no significant drug–drug interaction was found
between sunitinib and irinotecan.
Table 5 Summary of pharmacokinetic values (arithmetic mean (coefficient of variation)) for sunitinib, SU012662, sunitinib+SU012662, irinotecan, and its
active metabolite SN-38 for all doses combined (paired observations only)
Pharmacokinetic
parameter
Sunitinib alone
C0D–7, mean (CV%)
Irinotecan alone
C1D1, mean (CV%)
Sunitinibþirinotecan
C2D1, mean (CV%)
Geometric mean ratio
(C2D1/C0D–7 or C2D1/C1D1)
Sunitinib (n¼18)
a
Tmax (h)
b 8 (4–24) NA 8 (2–29)
Tlast (h)
c 24.0 NA 24.0
Cmax (ngl
 1) 16.3 (39.2) NA 13.0 (31.8) 0.82
AUC0–last (nghml
 1) 266.5 (41.2) NA 225.5 (29.5) 0.88
SU012662 (n¼18)
a
Tmax (h)
b 7 (2–24) NA 24 (1.8–29)
Tlast (h)
c 24.0 NA 24.0
Cmax (ngml
 1) 2.4 (51.4) NA 3.6 (32.5) 1.6
AUC0–last (nghml
 1) 38.6 (54.4) NA 53.2 (30.9) 1.48
Total drug (n¼18)
a
Tmax (h)
b 8 (4–24) NA 9 (2–29)
Tlast (h)
c 24.0 NA 24.0
Cmax (ngml
 1) 18.5 (40.3) NA 16.2 (29.7) 0.90
AUC0–last (nghml
 1) 305.2 (42.1) NA 278.2 (28.7) 0.95
Irinotecan (n¼18–20)
c
Tmax (h)
b NA 1 (1–1.7) 1 (0.9–1.7)
Tlast (h)
c NA 24.0 24.0
Cmax (mgml
 1) NA 2.9 (21.3) 3.6 (26.8) 1.21
AUC0–last (mghml
 1) NA 14.9 (27.7) 16.9 (33.3) 1.12
AUC0–N (mghml
 1) NA 15.9 (29.3) 18.1 (34.0) 1.13
CL (lh
 1) NA 31.9 (30.3) 30.4 (28.8)
t1/2 (h) NA 6.3 (19.8) 6.6 (21.9)
SN-38 (n¼18–20)
c
Tmax (h)
b NA 1.1 (1.0–4.2) 1.5 (0.9–4.1)
Tlast (h)
c NA 24.0 24.0
Cmax (mgml
 1) NA 0.03 (51.4) 0.04 (50.0) 1.13
AUC0–last (mghml
 1) NA 0.31 (61.7) 0.36 (52.8) 1.20
Abbreviations: AUC0–N¼area under the plasma concentration–time curve (AUC) from time zero to infinity; AUC0–last¼AUC from time zero to the last quantifiable
sampling time point; C0D–7¼cycle 0 (screening) day –7; C1D1¼cycle 1 day 1; C2D1¼cycle 2 day 1; CL¼clearance; Cmax¼maximum plasma concentration;
CV¼coefficient of variation; NA¼not applicable; t1/2¼terminal elimination half-life; Tlast¼time when last sample collected; Tmax¼time to Cmax.
aPharmacokinetic parameters
estimated on C2D1 were corrected for carryover pre-dose concentrations where applicable.
bMedian and range values presented for the parameter Tmax.
cMedian value
reported for Tlast.
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relevant pharmacokinetic interactions occur when sunitinib is
administered on days 1–14 of a 21-day cycle with irinotecan given
on day 1. The MTD was defined as sunitinib 25mg per day (days
1–14) and irinotecan 250mgm
 2 on day 1; this combination was
reasonably well tolerated, but did not show preliminary anti-
tumour activity. Evidence of activity was observed at the higher
37.5mg per day dose, but this exceeded the MTD. Therefore, this
particular combination will not be pursued for further studies
in unselected patient populations. UGT1A1 genotyping was not
routinely performed in our study and may have been useful to
identify patients with the UGT1A1*28 polymorphism who required
irinotecan dose reduction. As a VEGFR tyrosine kinase inhibitor
combined with chemotherapy did not appear to have synergistic
antitumour activity in our study (as also observed in most phase
III, randomised trials, in contrast to an anti-VEGF monoclonal
antibody plus chemotherapy; Los et al, 2007), we do not
recommend further phase II or III studies with this combination.
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